Adverum Biotechnologies Presents Long-term Data through March 10, 2021 from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy in Treatment-experienced Wet AMD Patients at ARVO 2021
Home / Top News / Adverum Biotechnologies Presents Long-term Data through March 10, 2021 from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy in Treatment-experienced Wet AMD Patients at ARVO 2021 Adverum Biotechnologies Presents Long-term Data through March 10, 2021 from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy in Treatment-experienced Wet AMD Patients at ARVO 2021 AC – Inflammation was Mild and Decreasing over Time in Cohort 3 AC – Inflammation was Mild and Decreasing over Time in Cohort 3 VC – Inflammation was Mild and Decreasing over Time in Cohort 3 VC – Inflam...
Source: forextv.com